Effects of carvedilol on plasma levels of pro-inflammatory cytokines - in patients with ischemic and nonischemic dilated cardiomyopathy

Basit Öğe Kaydı
dc.contributor.authorKurum, Turhan
dc.contributor.authorTatli, Ersan
dc.contributor.authorYuksel, Mahmut
dc.date.accessioned2024-06-12T10:54:38Z
dc.date.available2024-06-12T10:54:38Z
dc.date.issued2007
dc.departmentTrakya Üniversitesien_US
dc.description.abstractWe prospectively investigated the effects of adding carvedilol to the standard treatment of ischemic and nonischemic dilated cardiomyopathy (DCM), by measuring the plasma levels of pro-inflammatory cytokines. Sixty patients with DCM (35 ischemic and 25 nonischemic) were divided into 2 subgroups: patients on standard therapy alone (digoxin, angiotensin-converting enzyme inhibitors, and diuretics) and patients on standard therapy plus carvedilol. Study participants' serum levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-2 (IL-2), and interleukin-6 (IL-6) were measured at the beginning and again at the end of the study. Left ventricular ejection fraction and left ventricular diastolic function were evaluated by means of radionuclide ventriculography In ischemic patients on carvedilol, levels of IL-6 and TNF-alpha dropped significantly (P= 0.028 and P=0.034, respectively). In ischemic patients on standard treatment plasma IL-2 levels were elevated after treatment (P=0.047). No significant differences occurred in IL-6 levels, while TNF-alpha levels were elevated (P=0.008). In nonischemic patients on carvedilol, IL-6 and TNF-alpha levels dropped significantly (P=0.018 and P=0.004, respectively). The left ventricular ejection fraction increased significantly (P=0.006). In nonischemic patients on standard treatment, no significant change occurred in any value. Carvedilol suppressed the plasma levels of TNF-alpha and IL-6 in both ischemic and nonischemic patients. The carvedilol effect was more pronounced in patients with nonischemic dilated cardiomyopathy than in those with ischemic disease.en_US
dc.identifier.endpage59en_US
dc.identifier.issn0730-2347
dc.identifier.issue1en_US
dc.identifier.pmid17420794en_US
dc.identifier.startpage52en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19124
dc.identifier.volume34en_US
dc.identifier.wosWOS:000245344000013en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTexas Heart Insten_US
dc.relation.ispartofTexas Heart Institute Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBiological Markers/Blooden_US
dc.subjectCardiomyopathy, Dilateden_US
dc.subjectCarbazoles/Therapeutic Useen_US
dc.subjectCarvedilolen_US
dc.subjectCytokines/Blooden_US
dc.subjectHeart Failure, Congestiveen_US
dc.subjectInterleukin-2en_US
dc.subjectInterleukin-6en_US
dc.subjectTumor Necrosis Factor-Alphaen_US
dc.subjectVentricular Function, Left/Drug Effectsen_US
dc.subjectChronic Heart-Failureen_US
dc.subjectLeft-Ventricular Functionen_US
dc.subjectTumor-Necrosis-Factoren_US
dc.subjectCirculating Levelsen_US
dc.subjectDouble-Blinden_US
dc.subjectPentoxifyllineen_US
dc.subjectDysfunctionen_US
dc.subjectMetoprololen_US
dc.subjectTrialen_US
dc.subjectTermen_US
dc.titleEffects of carvedilol on plasma levels of pro-inflammatory cytokines - in patients with ischemic and nonischemic dilated cardiomyopathyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu